 Home > Medical News > Latest Medical News > For adjuvant treatment of NSCLC!

For adjuvant treatment of NSCLC!

 Last Update: 2022-05-24
 Source: Internet
 Author: User

Tags

cell

number 1 copper

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 11, the CDE official website showed that BeiGene's tislelizumab + osperizumab combination therapy was approved for clinical use in adjuvant and neoadjuvant treatment of non-small cell lung cancer

From: CDE official website

Osperimab is a TIGIT monoclonal antibody independently developed by BeiGene.

According to the Insight database, BeiGene has launched a number of clinical trials of PD-1 + TIGIT combination therapy in China, covering indications such as esophageal squamous cell carcinoma, NSCLC, LS-SCLC, and large B-cell lymphoma

Reference source: Insight database

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

JCO: Gefitinib is used for postoperative adjuvant treatment of NSCLC, and it does not improve OS compared with chemotherapy (ADJUVANT-CTONG1104)

08-26

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

For adjuvant treatment of NSCLC!

Related Articles

JCO: Gefitinib is used for postoperative adjuvant treatment of NSCLC, and it does not improve OS compared with chemotherapy (ADJUVANT-CTONG1104)